| 314 | 0 | 331 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 苍麻化毒颗粒治疗呼吸道病毒感染的药效作用、调节炎症与免疫功能的作用已得到初步验证。本项研究旨在揭示苍麻化毒颗粒通过调节血清/粪便代谢与肠道菌群发挥药效作用的机制。方法 通过肺指数、病毒载量指标，评价苍麻化毒颗粒的药效作用。通过代谢组学与肠道菌群测序方法，分析苍麻化毒颗粒分别对血清/粪便代谢与肠道菌群的调节作用。结果 在血清代谢调节中FDR值<0.05且排名前十的差异代谢物中，苍麻化毒颗粒显著改善模型对照组异常表达的代谢物7种；显著调节模型对照组11条显著变化代谢通路中的5条，包括蛋白质代谢与吸收，癌症相关的中心碳代谢，矿物质吸收等；在粪便代谢调节中FDR值<0.05且排名前十的差异代谢物中，苍麻化毒颗粒显著改善模型对照组异常表达的代谢物2种；显著干预模型对照组26条显著变化代谢通路中的6条，包括精氨酸产物合成，肠道免疫网络与IgA生成，亚油酸代谢等。相关性分析结果显示同一种差异代谢物与多种代谢物密切相关。肠道菌群测序结果显示，各组样本间的物种组成存在一定差异，苍麻化毒颗粒可显著抑制模型对照组瘤胃球菌（属）相对丰度的降低。结论 苍麻化毒颗粒可以调节多条代谢通路，对肠道菌群具有一定的调节作用，其药效作用机制可能与之相关。
Abstract：Objective The therapeutic effects of Cangma Huadu Granules on respiratory viral infections, along with their ability to regulate inflammation and immune responses, have been preliminarily confirmed. This study seeks to further clarify how Cangma Huadu Granules exert their benefits by influencing serum/fecal metabolism and the gut microbiota.Methods The efficacy of Cangma Huadu Granules was assessed using the lung index and viral load. Metabolomics and gut microbiota sequencing were used to evaluate their regulatory impacts on serum/fecal metabolism and microbial composition. Results In serum metabolomics, among the top ten differential metabolites with an FDR < 0.05, Cangma Huadu Granules significantly restored seven metabolites that were abnormally expressed and noticeably modulated five of the 11 altered metabolic pathways in the model control group, including protein digestion and absorption, central carbon metabolism in cancer, and mineral absorption. In fecal metabolomics, among the top ten differential metabolites with an FDR < 0.05, Cangma Huadu Granules significantly restored two abnormal metabolites and regulated six of the 26 disturbed metabolic pathways in the model control group, such as arginine biosynthesis, intestinal immune network for IgA production, and linoleic acid metabolism. Correlation analysis indicated that a given differential metabolite was linked with several others. For example, prostaglandin E 2 displayed significant positive correlations with mesobilirubinogen and （–）-3-isothujone, and significant negative correlations with 3-methyl-L-tyrosine and 2-oxo-4-methylthiobutanoic acid. Gut microbiota sequencing showed differences in species composition among groups. Cangma Huadu Granules significantly prevented the decline in the relative abundance of Ruminococcus seen in the model control group. Conclusion Cangma Huadu Granules can influence multiple metabolic pathways and exert a measurable regulatory effect on the gut microbiota, which may contribute to their mechanism of action.
[1]Ma L,Ji L,Wang T,et al.Research progress on the mechanism of traditional Chinese medicine regulating intestinal microbiota to combat influenza a virus infection[J].Virol J,2023,20(1):260.DOI:10.1186/s12985-023-02228-3.
[2]Zhou F,Zhao GZ,Li B,et al.Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza[J].Zhongguo Zhong Yao Za Zhi,2023,48(22):6216-6224.DOI:10.19540/j.cnki.cjcmm.20230804.501.
[3]Song J,Zhao J,Cai X,et al.Lianhuaqingwen capsule inhibits non-lethal doses of influenza virus-induced secondary Staphylococcus aureus infection in mice[J].JEthnopharmacol,2022,298:115653.DOI:10.1016/j.jep.2022.115653.
[4]Cui XR,Guo YH,Liu QQ.Cangma Huadu granules,a new drug with great potential to treat coronavirus and influenza infections,exert its efficacy through antiinflammatory and immune regulation[J].JEthnopharmacol,2022,287:114965.DOI:10.1016/j.jep.2021.114965.
[5]方晶，翁丽丽，王美怡，等.北苍术米泔水炮制前后化学成分变化及其对脾虚泄泻大鼠肠道真菌菌群的影响[J].中草药，2022,53(23):7372-7383.DOI:10.7501/j.issn.0253-2670.2022.23.007.
[6]杨瑾，杨照华.麻黄临床拓展运用举要[J].内蒙古中医药，2014,33(4):67.DOI:10.16040/j.cnki.cn15-1101.2014.04.071.
[7]Klara,Megyeri，áron,Dernovics,Zaid II,Al-Luhaibi et al.COVID-19-associated diarrhea.[J].World JGastroenterol,2021,27:3208-3222.DOI:10.3748/wjg.v27.i23.3208.
[8]杨超.中医药在流感防治中的应用进展与前景[J].中医药管理杂志，2023,31(6):226-228.DOI:10.16690/j.cnki.1007-9203.2023.06.078.
[9]韩雅俊，陈涛，王宗丹，等.中医药预防控制呼吸道传染病的探索[J].中国公共卫生管理，2022,38(2):221-224.DOI:10.19568/j.cnki.23-1318.2022.02.0020.
[10]王婷.基于文献计量的中医药治疗呼吸道感染的研究现状及趋势[J].数理医药学杂志，2025,38(6):440-449.DOI:10.12173/j.issn.1004-4337.202501067.
[11]李晓芸，朱汝南，赵林清.常用清热解毒类中药抗儿童呼吸道病毒感染的作用机制研究进展[J].病毒学报，2023,39(1):238-244.DOI:10.13242/j.cnki.bingduxuebao.004252.
[12]Li X,Liu Y,Xu G,et al.Plasma metabolomic characterization of SARS-Co V-2 Omicron infection[J].Cell Death Dis,2023,14:276.DOI:10.1038/s41419-023-05791-3.
[13]Huang H,Zhu S,Zhong S,et al.Fuzheng Xuanfei Huashi prescription suppresses inflammation in lipopolysaccharide-induced lung injury in mice toll-like recptor 4/nuclear transcription factorκB and cyclooxygenase-2/prostaglandin E2 pathway[J].JTradit Chin Med,2025,45(2):272-280.DOI:10.19852/j.cnki.jtcm.2025.02.018.
[14]Jordan PM,Günther K,Nischang V,et al.Influenza Avirus selectively elevates prostaglandin E(2) formation in pro-resolving macrophages[J].i Science,2023,27(1):108775.DOI:10.1016/j.isci.2023.108775.
[15]包晟川，闫曙光，陈婷，等.肺肠合治法治疗肺系疾病的研究进展[J].中国实验方剂学杂志，2022,28(8):116-122.DOI:10.13422/j.cnki.syfjx.20220708.
[16]杨春霞，白洁，臧东静，等.基于肺肠微生态探讨健脾方剂治疗呼吸道感染的新思路[J].世界中医药，2021,16(20):3100-3104.DOI:10.3969/j.issn.1673-7202.2021.20.025.
[17]赵佳明，李滢，吴毓薇，等.益生菌抗流感病毒作用及其机制研究进展[J].病毒学报，2024,40(4):877-886.DOI:10.13242/j.cnki.bingduxuebao.004533.
[18]Alshinnawy AS,Badiea EA,Swelam MS,et al.Decoding the gut microbiota in multiple sclerosis using nanopore long-read sequencing:insights into disease severity and subtypes[J].Mol Neurobiol,2025,62(11):14245-14260.DOI:10.1007/s12035-025-05194-9.
[19]Huang F,Wang H,Guan F,et al.Association between gut microbiota and blood lipid profile in Chinese adults aged 18-59 years with normal body weight in 2018[J].Wei Sheng Yan Jiu,2025,54(5),715-721.doi:10.19813/j.cnki.weishengyanjiu.2025.05.002.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.250363
中图分类号:R285
引用信息:
[1]崔煦然,刘清泉.基于代谢组学与肠道菌群测序探讨苍麻化毒颗粒治疗呼吸道感染的潜在机制[J].病毒学报,2026,42(01):101-114.DOI:10.13242/j.cnki.bingduxuebao.250363.